NASDAQ:TERN Terns Pharmaceuticals (TERN) Stock Price, News & Analysis $9.01 +0.22 (+2.50%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$8.86▼$9.2250-Day Range$5.86▼$9.9952-Week Range$3.26▼$10.03Volume572,361 shsAverage Volume999,000 shsMarket Capitalization$582.74 millionP/E RatioN/ADividend YieldN/APrice Target$14.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Terns Pharmaceuticals alerts: Email Address Terns Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside60.9% Upside$14.50 Price TargetShort InterestHealthy4.62% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment0.92Based on 5 Articles This WeekInsider TradingSelling Shares$509,760 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.41) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.57 out of 5 starsMedical Sector91st out of 936 stocksPharmaceutical Preparations Industry32nd out of 436 stocks 3.4 Analyst's Opinion Consensus RatingTerns Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageTerns Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Terns Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.62% of the float of Terns Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTerns Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Terns Pharmaceuticals has recently decreased by 26.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTerns Pharmaceuticals does not currently pay a dividend.Dividend GrowthTerns Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTerns Pharmaceuticals has received a 58.77% net impact score from Upright. Terns Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Physical diseases", and "Creating knowledge". The positive contribution in the "Physical diseases" impact category is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Terns Pharmaceuticals is -0.95. Previous Next 3.3 News and Social Media Coverage News SentimentTerns Pharmaceuticals has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Terns Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for TERN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added Terns Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Terns Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $509,760.00 in company stock.Percentage Held by Insiders15.10% of the stock of Terns Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions98.26% of the stock of Terns Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Terns Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Terns Pharmaceuticals are expected to decrease in the coming year, from ($1.41) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Terns Pharmaceuticals is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Terns Pharmaceuticals is -7.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTerns Pharmaceuticals has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Terns Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public. About Terns Pharmaceuticals Stock (NASDAQ:TERN)Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.Read More TERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TERN Stock News HeadlinesJuly 18, 2024 | insidertrades.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Sells $509,760.00 in StockJuly 20, 2024 | fool.comCan These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?July 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.July 18, 2024 | americanbankingnews.comTerns Pharmaceuticals (NASDAQ:TERN) Shares Gap Down to $9.99July 18, 2024 | americanbankingnews.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Director Carl L. Gordon Sells 50,976 Shares of StockJune 21, 2024 | globenewswire.comTerns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference ParticipationJune 3, 2024 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)May 30, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in Upcoming June Investor ConferencesJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 17, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in UBS Obesity Therapeutics DayMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)May 14, 2024 | markets.businessinsider.comHold Rating on Terns Pharmaceuticals Pending Clinical Trial OutcomesMay 13, 2024 | finanznachrichten.deTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 13, 2024 | finance.yahoo.comTerns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss ProjectionsMay 13, 2024 | globenewswire.comTerns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | globenewswire.comTerns Pharmaceuticals Announces Leadership ChangesMay 7, 2024 | globenewswire.comTerns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024May 3, 2024 | globenewswire.comTerns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)See More Headlines Receive TERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TERN CUSIPN/A CIK1831363 Webwww.ternspharma.com Phone650-525-5535FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Target$14.50 High Stock Price Target$23.00 Low Stock Price Target$5.50 Potential Upside/Downside+60.4%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-90,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-35.54% Return on Assets-33.83% Debt Debt-to-Equity RatioN/A Current Ratio27.85 Quick Ratio27.85 Sales & Book Value Annual Sales$1 million Price / Sales584.68 Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book2.19Miscellaneous Outstanding Shares64,677,000Free Float54,911,000Market Cap$584.68 million OptionableNot Optionable Beta-0.37 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Erin Quirk M.D. (Age 53)President & Head of Research & Development Comp: $1.06MDr. Mark Joseph Vignola Ph.D. (Age 46)CFO & Treasurer Comp: $974.16kMr. Seokho Yoon Esq. (Age 46)COO, General Counsel & Secretary Comp: $921.05kMs. Amy L. Burroughs M.B.A. (Age 53)CEO & Director Dr. Jeffrey R. Jasper Ph.D.Senior VP & Head of ResearchDr. Emil T. Kuriakose M.D. (Age 44)Chief Medical Officer Ms. Melita Sun Jung (Age 47)Chief Business Officer More ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTInozyme PharmaNASDAQ:INZYEnanta PharmaceuticalsNASDAQ:ENTAAquestive TherapeuticsNASDAQ:AQSTEnzo BiochemNYSE:ENZView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 64,018 shares on 7/26/2024Ownership: 0.273%Carl L GordonSold 50,976 sharesTotal: $509,760.00 ($10.00/share)Salem Investment Counselors Inc.Bought 371,600 shares on 7/11/2024Ownership: 0.575%Simplicity Wealth LLCBought 10,561 shares on 7/10/2024Ownership: 0.016%Virtu Financial LLCBought 44,307 shares on 5/20/2024Ownership: 0.069%View All Insider TransactionsView All Institutional Transactions TERN Stock Analysis - Frequently Asked Questions How have TERN shares performed this year? Terns Pharmaceuticals' stock was trading at $6.49 at the beginning of the year. Since then, TERN shares have increased by 38.8% and is now trading at $9.01. View the best growth stocks for 2024 here. How were Terns Pharmaceuticals' earnings last quarter? Terns Pharmaceuticals, Inc. (NASDAQ:TERN) announced its earnings results on Monday, May, 13th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.06. When did Terns Pharmaceuticals IPO? Terns Pharmaceuticals (TERN) raised $101 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO. Who are Terns Pharmaceuticals' major shareholders? Top institutional shareholders of Terns Pharmaceuticals include Salem Investment Counselors Inc. (0.57%), Bank of New York Mellon Corp (0.27%) and Simplicity Wealth LLC (0.02%). Insiders that own company stock include Orbimed Advisors Llc, Hongbo Lu, Biosciences Fund V LP Lav and Vivo Opportunity, Llc. View institutional ownership trends. How do I buy shares of Terns Pharmaceuticals? Shares of TERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TERN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
